Raise closed, search for fresh raises on Seedstage

Rochester, NY

Expanding a patient-centered platform to improve access to cancer treatments and accelerate clinical trial participation.

• Proven business model: Over $12 million in booked revenue from 20 pharmaceutical and biotech companies.
• Founded by survivors: Led by cancer survivors and caregivers focused on improving patient outcomes.
• Established patient community: 50 million patient interactions to date, supporting clinical trial recruitment and patient insights.
• Growing market demand: Positioned to meet increased needs from new FDA requirements emphasizing patient experience.
• Strategic investor backing: Backed by notable investors including The Omidyar Group and Michigan Capital Network.

Gryt Health is raising funds to expand its healthtech platform, focused on improving patient access to clinical trials and advancing equitable treatment development in oncology and other therapeutic areas. Founded by cancer survivors and caregivers, Gryt connects patients with new treatment opportunities through its established patient engagement platform. The company addresses challenges faced by pharmaceutical and biotech companies in reaching patients, providing services such as patient activation, clinical trial recruitment, patient experience research, and advocacy initiatives. Gryt’s solutions align with new FDA requirements mandating the integration of patient experience in medicine development.

Proceeds from the offering will support the scaling of Gryt’s proven business model, which has generated over $12 million in revenue to date and maintains a strong sales pipeline with major pharmaceutical and biotech clients. Gryt’s approach leverages a globally engaged patient community, with over 50 million interactions, to deliver patient insights and accelerate research outcomes. The company’s strategy includes expanding its services across additional disease areas and sectors within healthcare, while enhancing its technology platform and broadening its impact. With an experienced team and partnerships already in place, Gryt is positioned to further penetrate the oncology space and grow its presence across new regions and therapeutic areas.

Company Info

Gryt Health provides a patient engagement platform and services to improve access to new cancer treatments and support pharmaceutical companies in clinical trial recruitment and patient research.

Gryt Health is a health technology company focused on improving access to new cancer treatments and enhancing patient engagement. Founded by cancer survivors and caregivers, Gryt Health offers services such as clinical trial patient activation, patient experience research, and patient engagement platforms, working primarily with major pharmaceutical, biotech, and clinical research organizations. Their platform enables patients to navigate their diagnoses, learn about treatment options, and actively participate in clinical research, while providing pharmaceutical companies with patient-driven insights and support in clinical trial recruitment and patient-focused drug development. Gryt Health has established a large patient community with over 50 million interactions and has secured more than $12 million in revenue from partnerships with over 20 pharmaceutical and biotech companies.

The company’s business model addresses systemic challenges in the healthcare industry, including lack of patient awareness about clinical trials and precision treatments. Gryt Health leverages its platform to engage patients often overlooked by traditional channels, providing transparent, patient-first solutions. The company’s services align with new FDA requirements emphasizing patient experience in medicine development. With a strong team of experts from pharma, research, tech, and advocacy sectors, Gryt Health has completed 80 contracts and maintains a sales pipeline worth $5 million. Their current focus is on expanding their technology platform, scaling across new therapeutic areas, and leveraging cross-selling opportunities. Gryt Health projects significant growth, aiming to double revenue in both 2024 and 2025.